SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ — Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona’s investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company’s…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
